Filing Analysis
Quince Therapeutics, Inc. has filed an amendment to its 8-K to correct and confirm the implementation of a 1-for-20 reverse stock split. The split is scheduled to become effective on June 29, 2026, with trading on a split-adjusted basis commencing June 30, 2026.
🚩 Red Flags
- Implementation of a reverse stock split is often used to maintain Nasdaq listing requirements regarding minimum bid price.
- Significant reduction in total shares outstanding (from ~19.5M to ~0.97M).
📋 Key Facts
- Reverse stock split ratio: 1-for-20.
- Effective date of Certificate of Amendment: June 29, 2026, at 11:59 pm ET.
- Split-adjusted trading commences on Nasdaq Global Select Market on June 30, 2026.
- Pre-split shares outstanding: 19,559,257; Post-split shares outstanding: approximately 977,963.
- New CUSIP number (22053A305) effective June 30, 2026.
- Fractional shares will be rounded up to the next whole number rather than issued.
Quince Therapeutics, Inc. is implementing a 1-for-20 reverse stock split effective June 29, 2026. The move aims to consolidate shares and will result in a significant reduction of total outstanding common stock.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing requirements or signal distress)
- Significant reduction in share count/liquidity (from ~19.5M to ~0.97M shares)
📋 Key Facts
- Reverse stock split ratio: 1-for-20
- Effective date/time: 11:59 pm ET on June 29, 2026
- Trading adjustment: Shares will trade on a split-adjusted basis starting market open on June 30, 2026
- Pre-split shares outstanding: 19,559,257
- Post-split shares outstanding (approximate): 977,963
- New CUSIP number: 22053A305
- Fractional shares will be paid in cash instead of issued as stock.
Quince Therapeutics, Inc. has officially regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company successfully maintained a closing bid price of at least $1.00 for ten consecutive business days between October 29 and November 11, 2024.
🚩 Red Flags
- Historical delisting risk: The company was under threat of delisting due to low share price for several months.
📋 Key Facts
- The Company received written notice from Nasdaq on November 12, 2024, confirming compliance with Rule 5450(a)(1).
- Compliance was achieved by maintaining a closing bid price of $1.00 or higher for 10 consecutive business days (Oct 29, 2024 – Nov 11, 2024).
- The previous non-compliance notice was issued on June 20, 2024.
- The deadline to regain compliance was December 17, 2024.
Quince Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2024, and provided recent business highlights via a press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Announcement date: November 13, 2024
- The filing includes results of operations and financial condition under Item 2.02.
Quince Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2024, and provided recent business highlights via a press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Announcement date: August 13, 2024
- The filing includes results of operations and financial condition under Item 2.02.
Quince Therapeutics received a notice from Nasdaq stating it is no longer in compliance with the minimum bid price requirement of $1.00 per share. The company has an initial 180-day period to regain compliance by December 17, 2024.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5450(a)(1)).
- Failure to maintain minimum bid price requirement.
- Risk of delisting if compliance is not met by the end of the extension periods.
📋 Key Facts
- Received written notice from Nasdaq on June 20, 2024.
- The deficiency is due to the closing bid price being below $1.00 for the last 34 consecutive trading days.
- Initial compliance period expires December 17, 2024; requires a minimum of 10 consecutive trading days at or above $1.00.
- Potential for an additional 180-day extension if the company transfers to The Nasdaq Capital Market and meets its specific listing standards.
Quince Therapeutics, Inc. held its Annual Meeting of Stockholders on June 5, 2024, where shareholders approved a significant one-for-ten reverse stock split and the election of three Class II directors.
🚩 Red Flags
- Approval of a 1-for-10 reverse stock split, which is often used to maintain Nasdaq listing compliance or improve share price perception but can be viewed negatively by the market.
- High number of broker non-votes in director elections (over 14 million shares), indicating significant lack of participation or proxy solicitation issues for certain nominees.
📋 Key Facts
- Annual Meeting held via live webcast on June 5, 2024.
- Shareholders approved a 1-for-10 reverse stock split (Proposal Two).
- Three Class II directors were elected: Dirk Thye, M.D., David A. Lamond, and Luca Benatti, Ph.D.
- BDO USA, P.C. was ratified as the independent registered accounting firm for fiscal year 2024.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- Quorum represented approximately 75.34% of total outstanding shares.
Quince Therapeutics, Inc. announced the appointment of Rajiv Patni to its Board of Directors, effective February 15, 2024.
📋 Key Facts
- Rajiv Patni appointed as a Class III director, effective February 15, 2024.
- Term expires at the Company's 2025 Annual Meeting of Stockholders.
- Annual retainer set at $38,000 per year under the Amended and Restated Outside Director Compensation Policy.
- Grant of stock options for 54,000 shares of common stock under the 2019 Equity Incentive Plan.
- Options vest in equal annual installments over a 3-year period subject to continued service.
Quince Therapeutics, Inc. announced that the Compensation Committee has approved stock option grants for executive officers and determined there will be no salary increases for 2024.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Effective grant date for new stock options is February 1, 2024.
- Options vest in equal monthly installments over a four-year period.
- CEO Dirk Thye to receive 1,500,000 stock options and a $302,500 bonus.
- President Charles Ryan to receive 145,000 stock options and a $70,000 bonus.
- CBO/COO Brendan Hannah to receive 600,000 stock options and a $178,500 bonus.
- No salary increases were approved for executive officers for the year 2024.
Quince Therapeutics, Inc. filed an amendment to its previous 8-K to provide required historical financial statements and pro forma information following its acquisition of EryDel S.p.A.
🚩 Red Flags
- Delayed filing of required financial information (the amendment is being filed to satisfy the 71-day requirement for Item 9.01(a) and 9.01(b)).
📋 Key Facts
- The filing is an Amendment (8-K/A) to a report originally filed on October 23, 2023.
- The amendment provides historical audited financial statements for EryDel S.p.A. for the years ended December 31, 2022, and 2021.
- Includes unaudited condensed consolidated financial statements for EryDel as of three and nine months ended September 30, 2023, and 2022.
- Provides unaudited pro forma condensed combined balance sheet (as of Sept 30, 2023) and statement of operations (nine months ended Sept 30, 2023; year ended Dec 31, 2022).
- The acquisition was executed via a Stock Purchase Agreement dated July 21, 2023.
Quince Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement. Following a period of non-compliance where the stock traded below $1.00, the company met the criteria by maintaining a closing bid price of $1.00 or greater for 13 consecutive business days.
🚩 Red Flags
- Historical non-compliance with Nasdaq minimum bid price requirements indicates significant recent volatility or downward pressure on share price.
📋 Key Facts
- The Company was previously notified on December 4, 2023, that it was non-compliant with Nasdaq Listing Rule 5450(a)(1) due to the stock trading below $1.00 for 30 consecutive business days.
- Nasdaq provided a compliance deadline of June 3, 2024.
- As of December 29, 2023, the Company confirmed it maintained a closing bid price of $1.00 or greater for 13 consecutive business days (from Dec 11 to Dec 28, 2023).
- Nasdaq has officially notified the Company that the matter regarding minimum bid price compliance is now closed.